FARE - Food Allergy Research & Education Logo

Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT

Study Purpose

Open label study with peanut oral immunotherapy (OIT). Peanut allergic children aged >1 and <4 years of age will be randomized 2:1 to: 1. Peanut OIT with slow up-dosing (40-60 weeks) up to a maintenance dose of 286 mg daily oral peanut protein and. 2. Control group with peanut allergic children who do not undergo OIT. 3. In addition, a group of healthy children without allergic diseases will be included in the study. The primary outcome, sustained unresponsiveness (i.e. tolerance) to 600 mg peanut protein after 3 years of OIT, efficacy and safety will be compared between group 1 and 2. Group 3 is a control group for analyses of immunological markers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 1 Year - 3 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Children 1 - <4 years old at inclusion.
  • - Positive baseline challenge at a maximum of the 250 mg peanut protein-dose with at least one objective symptom, or positive peanut challenge performed in the clinic in a similar way within 1 year from study start.
  • - IgE-ab to peanut and/or Ara h 2 ≥0.1 kUA/l, analyzed within 12 months from start of study.
  • - Written consent for participation in the study from both Guardians.

Exclusion Criteria:

  • - Other serious illness.
  • - Previously life-threatening anaphylaxis (intensive care), regardless of the triggering agent.
  • - A history of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, severe chronic gastroesophageal reflux disease (GERD), symptoms of dysphagia, unclear recurrent GI disorders.
  • - Participation in another intervention study, if included in intervention Group.
  • - Severe uncontrolled asthma.
- Ongoing medication with biological drugs or oral steroids

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04511494
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Karolinska Institutet
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Anna Asarnoj
Principal Investigator Affiliation Karolinska Institutet
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Sweden
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Peanut Allergy
Additional Details

Problem: Today there is no clinically available treatment for peanut allergy. Oral Immunotherapy (OIT) studies have shown promising results, particularly in younger children (<4 years). Intervention: Peanut OIT in children aged >1 and <4 years with peanut allergy (clinical symptoms at peanut challenge and IgE >0.1 kU /l to peanut and/or Ara h 2). Comparison: Three groups are compared. Peanut allergic children are randomized 2:1 to group 1 (active OIT) or group 2 (control). Group 3 consists of age-matched healthy controls: Group 1; Children with peanut allergy receiving peanut OIT, slow up-dosing, 40-60 weeks, until the maintenance dose 286 mg peanut protein. Three years' treatment. Group 2; Age-matched children with peanut allergy who do not undergo OIT peanut. Peanut challenge one and three years after inclusion. Group 3; Healthy, non-allergic, age-matched children. No challenges are performed in this group. Inclusion of study subjects: A review of samples sent to the Karolinska University Laboratory for IgE-ab responses to peanut/Ara h 2 for children in the Stockholm area aged 1-<4 years is used for identification of potential participants to whom a letter is sent with information about the study. The families are randomized 2:1 to OIT or control group, group 1 or group 2. Children without allergies, healthy Controls (group 3), will be identified through the day surgery at Astrid Lindgren's Children's Hospital. Outcomes: The primary outcome is defined as sustained unresponsiveness to 775 mg peanut protein (cumulative dose) at an open oral peanut challenge 4 weeks after 3 years of OIT was stopped (group 1 and 2). Secondary outcomes are adverse events among peanut allergic children with/without OIT treatment (group 1 and 2), and changes in quality of life parameters and immunological markers (group, 1, 2, 3).

Arms & Interventions

Arms

Active Comparator: OIT peanut

Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.

No Intervention: Peanut avoidance

Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.

No Intervention: Healthy controls

Control Group with non-allergic, age-matched children. No challenges are performed in this group.

Interventions

Dietary Supplement: - Peanut (bamba)

OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Forskningsenheten Södersjukhuset AB, Stockholm, Sweden

Status

Recruiting

Address

Forskningsenheten Södersjukhuset AB

Stockholm, ,

Site Contact

Carina Uhl

smacho.sodersjukhuset@sll.se

0725-993782

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.